VivoGenie Biosimilar Antibodies
Fc-mutated VivoGenie biosimilars for in vivo research
90+ functional-grade, ultra-low-endotoxin biosimilar antibodies engineered for pre-clinical in vivo studies — PK/PD, mechanism-of-action and efficacy testing in animal models.
Why Choose VivoGenie Biosimilar Antibodies?
Purpose-built for pre-clinical in vivo work — where endotoxin, aggregation and Fc effector function actually matter.
In vivo ready
Fc mutated for pre-clinical studies, minimizing off-target immune effector function in animal models.
Ultra-low endotoxin
≤1 EU/mg levels validated by the LAL method — safe for in vivo administration.
High purity
≥95% purity and ≥95% monomer (verified by SEC), formulated in sterile PBS with no carrier proteins.
Broad target coverage
PD-1, PD-L1, CTLA-4, HER-2, TNF-α and 80+ more targets, including checkpoint and cytokine biosimilars.
Explore the Full Biosimilar Range
Need a different format? Browse the other two Assay Genie biosimilar ranges.
All Biosimilar Antibodies
Browse the complete catalog of 240+ biosimilar antibody targets across all three ranges.
- 240+ biosimilar antibodies
- 42+ targets covered
- cGMP manufactured, ≥98% purity
Reference Biosimilars
Nearly identical to the original reference biologic — the standard choice for in vitro assay development and comparison studies.
- 100+ reference biosimilars
- ISO 9001:2015 manufactured
- Validated for ELISA, flow cytometry & WB
Conjugated Biosimilars
Directly labeled with fluorescent dyes or enzymes for fast detection and quantification — no secondary antibody required.
- 100+ conjugated biosimilars
- Biotin, FITC, APC, PE, DyLight®488, HRP
- Ideal for ELISA, flow cytometry, WB, IF & SPR
Popular VivoGenie Biosimilars
Search our top VivoGenie targets — each card links directly to its in vivo biosimilar antibody product page.
How VivoGenie Biosimilars Are Made
Assay Genie’s VivoGenie pipeline adapts our standard biosimilar process specifically for in vivo compatibility, from reference biologic to a validated, animal-study-ready product.
- Select and characterize the reference biologic
- Express with Fc-mutation for in vivo compatibility
- Purify to ≥95% purity with ultra-low endotoxin (≤1 EU/mg)
- Validate via SEC, SDS-PAGE and LAL testing for in vivo readiness
VivoGenie Biosimilar QC & Specification Data
From reference biologic to validated, in vivo-ready biosimilar in four controlled steps.
Every lot undergoes extensive quality control to ensure lot-to-lot reproducibility. With low endotoxin levels (≤1.0 EU/mg) and minimal aggregation (≥95% monomer verified by SEC), VivoGenie biosimilars are formulated in sterile PBS (pH 7.2) with no preservatives, stabilizers or carrier proteins.
- ≤1 EU/mg endotoxin, verified by LAL method
- ≥95% purity, validated by SDS-PAGE
- ≥95% monomer, verified by SEC
- Sterile PBS (pH 7.2), no preservatives or stabilizers
What Researchers Say
“I ordered from Assay Genie for the first time and would like to share my satisfied impression. The article (Bevacizumab; IVMB0232) was used as a positive control and works excellently in Biacore SPR measurements and VEGF bioassay.”
G. Carsten, Fraunhofer (2024)cGMP & ISO Certification
Quality is at the core of everything we do.
Manufactured in state-of-the-art facilities, our VivoGenie biosimilar antibodies meet the highest standards, including current Good Manufacturing Practice (cGMP), ISO 9001:2015 and ISO 13485:2016 certifications — ensuring consistent quality, customer-focused innovation and reliable performance in every batch.
Frequently Asked Questions
What are research-grade biosimilars?
Research-grade biosimilars are laboratory-produced proteins designed to mimic the structure and function of approved biologic drugs. They are used in preclinical studies, assay development and other non-clinical applications.
How do research-grade biosimilars differ from therapeutic biosimilars?
Research-grade biosimilars are intended for laboratory and research purposes only. They are not subject to the same regulatory scrutiny as therapeutic biosimilars, which must undergo clinical trials and approval processes for patient use.
Are research-grade biosimilars the same as reference biologics?
No. Research-grade biosimilars are designed to be similar in structure and function to reference biologics but are not identical. They are primarily used for assay development, drug screening and in vitro/in vivo research.
Are research-grade biosimilars produced using the same expression systems as the original biologics?
They may be produced in similar systems (e.g., CHO cells, E. coli, yeast), but there can be differences in post-translational modifications, glycosylation patterns or impurities.
How is the quality of research-grade biosimilars ensured?
Quality is assessed through purity analysis (SDS-PAGE, HPLC, mass spectrometry), bioactivity assays and binding affinity tests (e.g., ELISA, SPR, BLI).
What are common applications of research-grade biosimilars?
Preclinical drug screening; assay development and validation (ELISA, Western blot, flow cytometry); mechanism of action studies; and comparative studies against reference biologics.
Can research-grade biosimilars be used in animal studies?
Yes, VivoGenie biosimilars are specifically Fc-mutated and formulated with ultra-low endotoxin for use in in vivo models to study pharmacokinetics, pharmacodynamics and efficacy before moving to clinical-grade biosimilars.
Got a Question?
Tell our PhD-level technical team which target or reference biologic you need for your in vivo study, and we’ll help you find the right VivoGenie biosimilar.
Ask Our Team Browse VivoGenie Biosimilars